Cardiogenic shock (CS) from all causes has shown a very high mortality rate. The trial's aim is to compare the surviving rate at one and six months as well as recurrences at six months in CS depending on its etiology.

We retrospectively reviewed from December 2014 until May 2018 in a monocentric observational study, 290 patients’ files, hospitalized for CS. 264 were included and then split into two groups: ACS-related cardiogenic shock (n=108) versus cardiomyopathy related cardiogenic shock (n=156). Patients with another etiology for CS were excluded from the present study. The inclusion criteria were: adult patient, hospitalized for CS or developping one during hospitalization. The primary composite end-point: death (at 1 and 6months) were accurately notified. Recurrence at 6months was the secondary end-point.

No significant difference was found between the two groups regarding the survival at one or six months. The survival rate at one month in the ACS was about 73.6% versus 65.6% in the cardiomyopathy group (P=0.187) whereas the survival rate at six months was 63.2% for the ACS versus 60% for cardiomyopathys (P=0.517). No significant difference was observed in this study when we compared the recurrence rate, with 16.2% in the cardiomyopathy group versus 14.6% in the ACS group (P=0.729). Secondary analysis found that coronary revascularization (P=0.010), transfusion (P=0.033), use of IV diuretics (P<0.001) were positive predictors of survival. The predictors of mortality (at 1 or 6month) with univariate analysis were patients over 72 years old (P=0.006) or with low left ventricular ejection fraction<35% (P=0.013), as well as the use of amins drugs>5days (P=0.011) or use of Epinephrine (P=0.004).

This study shows no significant difference comparing survival at one and six months or re-hospitalization at six months whether CS happens with a known cardiomyopathy or during an acute coronary syndrome.